Redeye comments on Lytix' first quarter report 2026. The positive ATLAS-IT-05 readout, together with the demonstration of abscopal effects in Verrica's phase II study in BCC, strengthens the case for ruxotemitide. 20/27 patients have been recruited in the ongoing NeoLIPA study in neoadjuvant melanoma, with a planned readout in H2 2026, a major catalyst, while Verrica plans to initiate a phase III programme in BCC this year.
LÄS MER
